Acesion Pharma is a Danish biotech company founded in 2011. We are aiming to develop more efficacious and safer drugs for the treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia. 
The scientific foundation of Acesion Pharma is the novel concept of treating AF by inhibiting the so-called SK channels. These are ion channels present in the heart where they are relevant for regulating the cardiac rhythm. Blocking this ion channel with a selective drug molecule constitutes a novel and promising target for developing improved treatment of AF.

Novo Holdings

Seed Capital

Wellcome Trust

Acesion Pharma

Acesion Pharma announces today the successful closure of an oversubscribed €45 million Series B Financing Round. Co-led by Canaan and Alpha Wave Global, LP, along with the support of the Global BioAccess Fund and existing investor Novo Holdings, the investment marks a significant leap forward in our mission to advance novel therapies for atrial fibrillation (AF).
 
With the capital raised, we are able to progress AP31969, our SK ion channel inhibitor tailored for chronic oral AF treatment, through clinical development. This company milestone builds upon strong pre-clinical and recent phase II proof-of-concept data with AP30663, our pioneering SK inhibitor for converting AF to normal sinus rhythm.
 
Read more here: [https://lnkd.in/estqmEm9]

Acesion Pharma is proud to announce the publication of our clinical Phase 2 data in the prestigious Nature Medicine Journal. The trial tested our first-in-class SK ion channel inhibitor AP30663's efficacy in converting Atrial Fibrillation (AF) to normal sinus rhythm with an intravenous infusion. AP30663 achieved a class leading 55% conversion rate resulting in a 99.9% probability of superiority over placebo, demonstrating the first-ever proof of mechanism for SK channel inhibition in AF.
 
In addition, we are pleased to announce the initiation of a Phase 1 trial for AP31969, an oral SK ion channel inhibitor targeting maintenance of sinus rhythm in AF with chronic treatment. We look forward to sharing more updates soon as we continue our work to change the AF treatment landscape. 
 
Read more: https://lnkd.in/du_4bY8Y 
 
#AcesionPharma #AFResearch #CardiacHealth 

On the back of showing clinical proof-of-concept with AP30663, a first-in-class SK channel inhibitor, we have been working hard to progress our second-generation SK channel inhibitor, AP31969 being developed for developed for chronic oral maintenance treatment to prevent atrial fibrillation recurrence.

With AP31969, we aim to solve the major concern with existing drugs; a high-risk of life-threatening cardiac arrhythmia, also known as proarrhythmia and we have generated a strong pre-clinical data package to substantiate this.

Learn more here: https://bit.ly/42Ad1Vf

#atrialfibrillation 

Organization Schema

CrUX Dataset

Person Schema

CrUX Top 50m

International Recruitment Manager

Kurt Kenning

Senior Research Scientist

Sofia Bomholtz

Bobby Soni

Morten Graugaard Døssing

Nils Edvardsson

Anders Gaarsdal Holst

Chief Medical Officer and Head of Development

Torgeir Vaage

Ulrik Sørensen

COO and Co-Founder

Breian Knudsen

Vice President CMC

Morten Grunnet

CSO, Board member and Co-Founder

Medical Companies (Top 10K)

European Union (EU) Companies With More Than 10 Employees (Top 10K)

European Union (EU) Companies With Less Than $10M in Revenue (Top 10K)

Pharmaceutical Companies with Early Stage Venture Funding

Acesion Pharma is a developer of medical drugs designed for the treatment of atrial fibrillation.  The company's medical drugs develop treatments for atrial fibrillation which is the most common type of cardiac arrhythmia by following the concept of inhibiting a type of ion channel in heart cells that is involved in generating the electrical signals that regulate the heart's rhythm, providing consumers with chronic treatment to prevent the recurrence of AF and maintain normal heart rhythm.

Alpha Wave Global

Canaan Partners

Series B - Acesion Pharma

Series A - Acesion Pharma

Venture Round - Acesion Pharma

Copenhagen

Hovedstaden

Denmark

Europe

Acesion Pharma reports new SK3 channel blockers for arrhythmia

Global VC deals for September 27, 2023

Acesion Pharma Closes Oversubscribed €45M Series B Financing Round

Endpoints News — #1806- DeepMind's Demis Hassabis on ...

ECI Partners Closes Twelfth Buyout Fund, at £1 Billion

Acesion Pharma Raises €45M in Series B Financing

Acesion Pharma Announces Positive Pre-Clinical Data for AP31969

Acesion Pharma announces positive phase 2 data from Atrial Fibrillation clinical trial – primary endpoint achieved

Thryv Therapeutics is a company focused on developing treatments for atrial fibrillation and other cardiac rhythm disorders.

Thryv Therapeutics

Blue Ash Therapeutics is a pharmaceutical company specializing in the development of drugs for atrial fibrillation and other cardiac rhythm disorders.

Blue Ash Therapeutics

Rhythm Therapeutics is a biotech company developing drugs for the medical treatment of atrial fibrillation and other cardiac arrhythmias.

Rhythm Therapeutics

Pfizer is a multinational pharmaceutical company involved in the development of various drugs, including treatments for atrial fibrillation.

Pfizer

GlaxoSmithKline is a leading pharmaceutical company that develops and manufactures a wide range of pharmaceutical products, including treatments for atrial fibrillation.

GlaxoSmithKline

Johnson & Johnson is a global healthcare company that develops and manufactures pharmaceuticals, medical devices, and consumer health products, including treatments for atrial fibrillation.

Johnson & Johnson

Acesion Pharma is a Danish biotech company focused on the development of innovative treatments for atrial fibrillation and other cardiac rhythm disorders. The company's lead candidate, AP30663, is designed to convert atrial fibrillation to sinus rhythm and maintain normal sinus rhythm in patients.

news impact assignment basic	general	Nov 21, 2024 8:04 AM	660a8bbb
public peers	general	May 16, 2024 7:33 AM	85fed049
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Oct 28, 2024 1:51 PM	bcb90049
crunchbase profile	general	Oct 28, 2024 2:45 PM	882288f0
li profile	general	May 16, 2024 7:33 AM	cd7423df
translate crunchbase fundingrounds	general	Nov 6, 2024 3:12 PM	bc0ba677
peers	general
news basic	general
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:ACESIONPHARMA

Acesion Pharma